

Once-Daily Injection Approved for Type 2 Diabetes and Moderate CKD



A once-daily injection has been approved in the UK for adults with type 2 diabetes and moderate renal impairment.

Approximately one million people in the UK have type 2 diabetes and around 40 percent of them are affected by moderate chronic kidney disease. Renal impairment is one of the most common long-term complications associated with diabetes and often becomes serious, debilitating or even fatal.

Now, Victoza® (liraglutide) from Novo Nordisk will be available to people who are affected by both conditions.

Victoza® removes the need for dose adjustments in these patients while maintaining glucose control.

According to Steve Bain, Professor of Medicine at Swansea University and Clinical Lead for the Diabetes Research Network, Wales, "The choice of glucose-lowering therapies available to adults with both conditions is currently limited. Victoza® has shown long-term blood glucose control in adults with type 2 diabetes and moderate renal impairment. The new licence extension will not only help these adults achieve glucose control, but will provide clinicians with an additional treatment option. This is paramount to the care of adults with both conditions".

It is estimated that type 2 diabetes costs the NHS approximately £21.8 billion and the complications of chronic kidney disease account for £753.8 million. These figures are expected to further increase to £35.6 billion for type 2 diabetes and £1.3 billion for kidney disease by 2035/36. Chronic kidney disease has to be frequently monitored because if it is left uncontrolled, it can progress to renal failure.

Since diabetes treatment options are quite limited for those with chronic kidney disease, Victoza® offers a ray of hope for such patients. In clinical trials, Victoza® has shown superior blood glucose reduction and significant weight reduction with no worsening of renal function as compared to placebo. The availability of this drug now increases prescribing options for clinicians to help patients control both conditions at the same time.

Source: [Hospital Pharmacy Europe](#)

Image Credit: Wikimedia Commons

Published on : Sat, 24 Jan 2015